Dnaprint Genomics Stock Probability Of Bankruptcy
DNAPrint Genomics' likelihood of distress is above 80% at the present time. It has very high risk of going through financial hardship in the upcoming years. DNAPrint Genomics' Chance of financial distress is determined by interpolating and adjusting DNAPrint Altman Z Score to account for off-balance-sheet items and missing or unfiled public information. All items used in analyzing the odds of distress are taken from the DNAPrint balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
DNAPrint |
DNAPrint Genomics Company chance of financial distress Analysis
DNAPrint Genomics' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current DNAPrint Genomics Probability Of Bankruptcy | Over 100% |
Most of DNAPrint Genomics' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DNAPrint Genomics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of DNAPrint Genomics probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting DNAPrint Genomics odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of DNAPrint Genomics financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
CompetitionBased on the latest financial disclosure, DNAPrint Genomics has a Probability Of Bankruptcy of 100%. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is notably lower than that of the firm.
DNAPrint Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DNAPrint Genomics' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DNAPrint Genomics could also be used in its relative valuation, which is a method of valuing DNAPrint Genomics by comparing valuation metrics of similar companies.DNAPrint Genomics is currently under evaluation in probability of bankruptcy category among its peers.
DNAPrint Fundamentals
| Return On Asset | -1.05 | |||
| Profit Margin | (2.36) % | |||
| Operating Margin | (7.31) % | |||
| Current Valuation | 5.21 M | |||
| Shares Outstanding | 644.61 M | |||
| Shares Owned By Institutions | 0.18 % | |||
| Price To Sales | 0.0003 X | |||
| Revenue | 2.43 M | |||
| Gross Profit | 754.07 K | |||
| EBITDA | (5.78 M) | |||
| Net Income | (12.35 M) | |||
| Cash And Equivalents | 134.35 K | |||
| Total Debt | 240 K | |||
| Current Ratio | 0.17 X | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (5.78 M) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 24 | |||
| Beta | 23.48 | |||
| Market Capitalization | 644 | |||
| Total Asset | 10.27 M | |||
| Retained Earnings | (45.53 M) | |||
| Working Capital | (9.35 M) | |||
| Current Asset | 1.89 M | |||
| Current Liabilities | 11.24 M | |||
| Net Asset | 10.27 M |
About DNAPrint Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DNAPrint Genomics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DNAPrint Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DNAPrint Genomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in DNAPrint Stock
If you are still planning to invest in DNAPrint Genomics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the DNAPrint Genomics' history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |